Sigrún Halldórsdóttir

Tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population

Björn Fagerberg, S. Edwards, T Halmos et al. · Diabetologia · 2005 · 114 citations · Full text

Insulin Resistance, Metabolic Syndrome, Diabetes Management +13

Association of Type D personality with unhealthy lifestyle, and estimated risk of coronary events in the general Icelandic population

Erla Svansdóttir, Johan Denollet, Sigrún Halldórsdóttir et al. · European Journal of Preventive Cardiology · 2012 · 67 citations · Full text

Retinopathy in old persons with and without diabetes mellitus: the Age, Gene/Environment Susceptibility—Reykjavik Study (AGES-R)

Elín Gunnlaugsdóttir, Sigrún Halldórsdóttir, Ronald Klein et al. · Diabetologia · 2011 · 47 citations · Full text

Gene/environment Susceptibility—reykjavik Study, Diabetic Retinopathy, Ocular Disease +8

Tesaglitazar, a dual peroxisome proliferator-activated receptor α/γ agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance

Herbert Schuster, Björn Fagerberg, S. Edwards et al. · Atherosclerosis · 2007 · 31 citations

Insulin Resistance, Metabolic Syndrome, Biochemistry +12

Changes in total cholesterol levels in Western societies are not related to statin, but rather dietary factors: the example of the Icelandic population

Laufey Steingrímsdóttir, Sigrún Halldórsdóttir, Karl Andersen et al. · European Heart Journal · 2012 · 17 citations · Full text